Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRATEGY: Tirofiban and Aspirin for Acute Penetrating Artery Territory Infarction
NCT05310968Phase 4Completed
- Sponsor
- Beijing Tiantan Hospital
- Start
- Nov 2022
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of tirofiban in branch atheromatous disease (BAD) and lacunar infarction (LACI), sponsored by Beijing Tiantan Hospital. Started Nov 2022; status: completed.
02
Drugs
tirofiban
03
Conditions
branch atheromatous disease (BAD)lacunar infarction (LACI)
Beyond the preview
Go deeper on NCT05310968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05310968.